Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Phase 1 trial suggests benefit of psilocybin in OCD treatmentThe Brown University Psychopharmacology Update · 2026-07-31Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.Journal of Psychopharmacology · 2026-06-27Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depressionPharmacological Research · 2026-06-10Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional surveymedRxiv · 2026-05-31Psilocybin shows mixed results for patients with treatment-resistant depressionThe Brown University Psychopharmacology Update · 2026-05-28Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessationThe Brown University Psychopharmacology Update · 2026-05-28Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headacheJournal of Psychopharmacology · 2026-05-28Psilocybin-induced neurocardiogenic syncope: a case reportPsychopharmacology · 2026-05-27Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-26Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybinJournal of Pre-Clinical and Clinical Research · 2026-05-11Prohedonic Effects of Psilocybin (COMP360) in a Touchscreen-Based Rodent Probabilistic Reward Task (Abstract ID: 227883)Journal of Pharmacology and Experimental Therapeutics · 2026-04-30PDE4B Inhibition and Psilocybin as Promising Approaches for Treating Methamphetamine Use Disorder: Preclinical Evidence From Rat Models (Abstract ID: 232554)Journal of Pharmacology and Experimental Therapeutics · 2026-04-30Effects of Psilocybin on Attentional Set-Shifting Following Chronic Unpredictable Stress in Rats (Abstract ID: 231339)Journal of Pharmacology and Experimental Therapeutics · 2026-04-30483. Acute Functional Brain Changes Associated With Psilocybin in Depression and Healthy Adults: A Systematic Review and Coordinate-Based Meta-AnalysisBiological Psychiatry · 2026-04-24Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in ratsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-04-18Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han ratsScience Letters · 2026-04-16Psilocybin and Psilocybe cubensis extract exhibit divergent behavioural and toxicological effects in ratsScience Letters · 2026-04-16An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive DisorderClinical Neuropharmacology · 2026-03-31The astrocytes in the prefrontal cortex contribute to the rapid antidepressant-like effects of psilocybin in the chronic restraint stress mouse modelProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-03-31In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5’-methoxy-N,N-dimethyltryptamine and O-acetylpsilocinArchives of Toxicology · 2026-03-30Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distributionCanadian Journal of Public Health · 2026-03-18Efficacy and Safety of Psilocybin in Treatment-Resistant Major DepressionJAMA Psychiatry · 2026-03-17A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorderJournal of Psychopharmacology · 2026-03-12Psilocin as a Broad Inhibitor of CYP450 Enzymes: Integrated In Vitro and In Silico EvidenceInstituto Politécnico do Porto · 2026-02-24Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamineGeneral Hospital Psychiatry · 2026-02-24Effects of Psilocybin and Select Pharmaceutical InteractionsMacEwan University Student eJournal · 2026-02-17Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescenceNeuropsychopharmacology · 2026-02-17Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literatureJournal of Psychopharmacology · 2026-02-15Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applicationsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-01-26Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experienceJournal of Psychopharmacology · 2026-01-25Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanismsNeuropharmacology · 2026-01-20Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysisPharmacological Reports · 2026-01-19Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocolsEuropean Neuropsychopharmacology · 2026-01-15The effect of psilocin on neurotransmitters release in the claustrum and on rat behaviorPharmacological Reports · 2026-01-04Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trialNeuroscience Applied · 2025-12-31Relationship between cardiovascular effects and psychedelic experiences under psilocybin in patients with treatment-resistant depressionNeuroscience Applied · 2025-12-31An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in miceJournal of Psychopharmacology · 2025-12-31Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and PsilocybinHuman Psychopharmacology Clinical and Experimental · 2025-12-31The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measuresJournal of Psychopharmacology · 2025-12-31Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure RisksUnknown journal · 2025-12-28The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin ExperienceJournal of Clinical Psychopharmacology · 2025-12-08Comment on: Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.Unknown journal · 2025-12-02Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trialProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2025-11-21Psilocybin Experiential Therapist Training: Insights from a World-First StudymedRxiv · 2025-11-16Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacyBMJ Supportive & Palliative Care · 2025-11-02Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trialsNeuropharmacology · 2025-11-01Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticityBiomedicine & Pharmacotherapy · 2025-10-29Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trialPilot and Feasibility Studies · 2025-10-27Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trialsNeuropharmacology · 2025-10-16Control group improvement lower in psilocybin trials for depressionThe Brown University Psychopharmacology Update · 2025-10-09Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behaviorProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2025-09-30Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in ratsBehavioural Pharmacology · 2025-09-24Compassionate use of psilocybin for treatment-resistant depression in GermanyThe Lancet Psychiatry · 2025-09-22High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley ratsJournal of Psychopharmacology · 2025-09-21Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the USJournal of Clinical Medicine · 2025-09-18Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed MiceACS Pharmacology & Translational Science · 2025-09-10Psilocybin Use in the Autism Spectrum Disorder: A Scoping ReviewClinical Neuropharmacology · 2025-08-31Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trialTherapeutic Advances in Psychopharmacology · 2025-08-31Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trialJournal of Psychopharmacology · 2025-08-28Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelicsJournal of Psychopharmacology · 2025-08-26Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorderNeuropharmacology · 2025-08-20Response to emotional stimuli weaker in SSRI users compared with psilocybinThe Brown University Psychopharmacology Update · 2025-08-03The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of PsilocinACS Pharmacology & Translational Science · 2025-07-07Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic MicePharmaceuticals · 2025-07-05Psychedelic drugs for the treatment of substance use disorders.Expert review of clinical pharmacology · 2025-06-30Synthesis of Psilocin, Psilocybin and 5-MeO-DMT Succinate, All Labelled With Carbon-14 at the Indole 2-PositionJournal of Labelled Compounds and Radiopharmaceuticals · 2025-06-30Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar ratsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2025-06-30Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depressionJournal of Psychopharmacology · 2025-06-30Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signalingInternational Immunopharmacology · 2025-05-26Role of endogenous serotonin in psychedelic-like effects of psilocybin in miceThe International Journal of Neuropsychopharmacology · 2025-05-24Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J micePsychopharmacology · 2025-05-15Pharmacokinetics (PK) of psilocybin and psilocin in plasma following intravenous administration of psilocin and oral administration of psilocybin to male beagle dogsJournal of Pharmacological and Toxicological Methods · 2025-04-30Psilocybin-assisted therapy shows range of benefits in cancer patientsThe Brown University Psychopharmacology Update · 2025-04-28Trial finds psilocybin improves symptoms in treatment-resistant depressionThe Brown University Psychopharmacology Update · 2025-04-28Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Unknown journal · 2025-04-21Psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamusJournal of Psychopharmacology · 2025-04-16Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional AnalysisPharmacopsychiatry · 2025-04-16Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathwayNaunyn-Schmiedeberg s Archives of Pharmacology · 2025-04-14Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trialNeuropsychopharmacology · 2025-04-08Psilocybin has a narrow therapeutic window as an antidepressant treatmentProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2025-03-31Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavementBMJ Open · 2025-03-31Utilizing Psychedelics to Enhance Well-Being: A Systematic Review.Unknown journal · 2025-03-30The effect of low-dose psilocybin on brain neurotransmission and rat behaviorProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2025-03-28Psilocybin-assisted therapy leads to personality shifts in patients with alcohol use disorderThe Brown University Psychopharmacology Update · 2025-03-26LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in MicePharmaceuticals · 2025-03-22IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic painPharmacological Research · 2025-03-16Psilocybin therapy might help frontline pandemic workersThe Brown University Psychopharmacology Update · 2025-03-02Evaluating the Influence of CYP450 Enzyme Inducers on the Efficacy of Psilocybin as a Treatment for Neuropsychiatric Disorders (Abstract ID: 167358)Journal of Pharmacology and Experimental Therapeutics · 2025-02-28Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine PathwaysPharmacology Research & Perspectives · 2025-02-24Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybinEuropean Journal of Pharmacology · 2025-01-26Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigationPsychopharmacology · 2025-01-06Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSDOpen Science Framework · 2024-12-31Alternative therapy for neurological and psychiatric disorders using psilocybinUnknown journal · 2024-12-31Psilocybin: revealing the enigmas of a revolutionary fungiSA pharmaceutical journal. · 2024-12-31Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar ratsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2024-12-31PolDrugs 2025: results of the third edition of the nationwide study on psychoactive substance use in the context of psychiatry and harm reduction.Frontiers in psychiatry · 2024-12-31Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent mannerNeuropharmacology · 2024-12-23Legal and Ethics Concerns of Psilocybin as Medicine.Unknown journal · 2024-12-11Psilocybin as a Disease-Modifying Drug-A Salutogenic Approach in Psychiatry.Unknown journal · 2024-11-30Psilocybin alters the circulating metabolomic profile in both non-clinical and clinical modelsBrain Behavior and Immunity · 2024-10-31Phytochemical screening, phenolic and flavonoid contents, psilocybin, antioxidant, and acetylcholinesterase inhibition activities of the aqueous extract from the fungi Cyathus striatus, Laternea dringii, and Marasmius haematocephalusBrazilian Journal of Science · 2024-10-31Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trialsJournal of Psychopharmacology · 2024-10-30Psilocybin for clinical indications: A scoping review.Unknown journal · 2024-08-12Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaireJournal of Psychopharmacology · 2024-08-12Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent EvidenceCurrent Psychopharmacologye · 2024-07-03Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depressionPsychopharmacology · 2024-07-03Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depressionTrials · 2024-07-02Effects of psilocybin on body weight, body composition, and metabolites in male and female micePhysiology & Behavior · 2024-07-01High Blood Pressure Among Psilocybin and Cannabis Consumers During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health StudyDrug and Alcohol Dependence · 2024-06-30Up-to-Date on clinical and preclinical studies of psilocybin therapyFolia Pharmacologica Japonica · 2024-06-29Review identifies factors associated with response to psilocybinThe Brown University Psychopharmacology Update · 2024-06-26Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi studyJournal of Psychopharmacology · 2024-06-17Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action”Frontiers in Psychiatry · 2024-06-03Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushroomsBritish Journal of Pharmacology · 2024-06-01A Case Report of Psilocybin-induced Psychosis in a Predisposed PatientClinical Psychopharmacology and Neuroscience · 2024-05-20Psilocybin as a new way for depression treatmentJournal of Education Health and Sport · 2024-05-14The Classical Psychedelic Psilocybin Mitigates Oxycodone WithdrawalJournal of Pharmacology and Experimental Therapeutics · 2024-05-12Psilocybin-induced anxiolytic effects supported by transient elevation of corticosteroneJournal of Pharmacology and Experimental Therapeutics · 2024-05-12Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushroomsPsychopharmacology · 2024-04-29In vitro and in vivo metabolism of psilocybin’s active metabolite psilocinFrontiers in Pharmacology · 2024-04-28Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in miceJournal of Psychopharmacology · 2024-04-27Effects of psilocybin, psychedelic mushroom extract and 5-hydroxytryptophan on brain immediate early gene expression: Interaction with serotonergic receptor modulatorsFrontiers in Pharmacology · 2024-04-17Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.Unknown journal · 2024-04-17Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depressionJournal of Psychopharmacology · 2024-03-21Patients with bipolar II disorder benefit from single dose of psilocybinThe Brown University Psychopharmacology Update · 2024-03-03Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insightsInternational Immunopharmacology · 2024-02-22Psilocybin and eugenol prevent DSS-induced neuroinflammation in miceBiocatalysis and Agricultural Biotechnology · 2024-01-24Do the therapeutic effects of psilocybin involve actions in the gut?Trends in Pharmacological Sciences · 2024-01-10Neural effects of psilocybin-treatment in patients with treatment-resistant depressionNeuroscience Applied · 2023-12-31Government-funded trial will test psilocybin as treatment for opioid use disorderPharmaceutical journal/The pharmaceutical journal · 2023-12-31Psilocybin may be as effective as escitalopram in treating depression, study suggestsPharmaceutical journal/The pharmaceutical journal · 2023-12-31The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Unknown journal · 2023-12-31Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recoveryTherapeutic Advances in Psychopharmacology · 2023-12-31Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, proof-of-principle, placebo-controlled and crossover, neuroimaging trial in depressionResearch Square · 2023-12-27Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT2A receptor agonist TCB-2 in male DBA/2J micePharmacology Biochemistry and Behavior · 2023-12-25Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.Unknown journal · 2023-11-06Anxiolytic behavior accompanied by the alteration of the intestinal bacteriome during psilocybin treatmentBrain Behavior and Immunity · 2023-10-31The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studiesJournal of Psychopharmacology · 2023-10-30Single dose of psilocybin improves depressive symptoms in Phase 2 studyThe Brown University Psychopharmacology Update · 2023-10-29Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocolEuropean Journal of Trauma & Dissociation · 2023-10-24Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual ExperiencesReligions · 2023-10-18Effects of psilocybin, the 5-HT2A receptor agonist TCB-2, and the 5-HT2A receptor antagonist M100907 on visual attention in male mice in the continuous performance testPsychopharmacology · 2023-10-18Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in ratsJournal of Psychopharmacology · 2023-10-15Psilocybin shows promising results in subjects continuing to use an antidepressantThe Brown University Psychopharmacology Update · 2023-10-03Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdalaNeuropsychopharmacology · 2023-09-25Psilocybin, escitalopram have comparable effects on personality in patients with depressionThe Brown University Psychopharmacology Update · 2023-09-02Acute effects of psilocybin, LSD, mescaline found to be similarThe Brown University Psychopharmacology Update · 2023-09-02Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in MiceACS Pharmacology & Translational Science · 2023-08-01Psilocybin und Funktionalität bei DepressionInFo Neurologie + Psychiatrie · 2023-07-31Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medicationNeuropsychopharmacology · 2023-07-12Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptomsJournal of Psychopharmacology · 2023-06-29Psilocybin intoxication did not affect daytime or sleep-related declarative memory consolidation in a small sample exploratory analysisEuropean Neuropsychopharmacology · 2023-06-16Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant useJournal of Psychopharmacology · 2023-06-07Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memoriesPsychopharmacology · 2023-06-01Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participantsNeuropsychopharmacology · 2023-05-24A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depressionJournal of Psychopharmacology · 2023-04-2496. An Open Label Study of Synthetic Psilocybin in Bipolar Type II DepressionBiological Psychiatry · 2023-04-09Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trialJournal of Psychopharmacology · 2023-03-19The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in MiceMolecules · 2023-03-13Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020Journal of Psychopharmacology · 2023-03-05Psychedelics: Science sabotaged by Social Media.Unknown journal · 2023-01-20Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J miceFrontiers in Pharmacology · 2023-01-03Effect of co-administration of low doses of psilocybin and mGluR2/3 antagonist LY341495 in chronic restraint stress model of depressionNeuroscience Applied · 2022-12-31Psilocybin as a treatment for anorexia nervosa: 6-week and 3-month follow-up resultsNeuroscience Applied · 2022-12-31Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatednessJournal of Psychopharmacology · 2022-12-31Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?Pharmaceuticals · 2022-12-30High dose of psilocybin effective for treatment-resistant depressionThe Brown University Psychopharmacology Update · 2022-12-26Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumptionJournal of Psychopharmacology · 2022-12-13Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy ParticipantsClinical Pharmacology & Therapeutics · 2022-12-11Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndromePsychopharmacology · 2022-12-04Therapeutic use of psilocybin: Practical considerations for dosing and administration.Unknown journal · 2022-11-30Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression.Journal of Psychopharmacology · 2022-11-25Body mass index (BMI) does not predict responses to psilocybin.Journal of Psychopharmacology · 2022-11-13Psilocybin-assisted therapy reduces heavy drinking in patients with AUDThe Brown University Psychopharmacology Update · 2022-11-02Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice.ACS Pharmacology & Translational Science · 2022-11-01Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.New England Journal of Medicine · 2022-10-31Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.Journal of Psychopharmacology · 2022-10-30P03-21 Magic mushrooms and psilocybin: pharmacokinetics, pharmacodynamics, and clinical applicationsToxicology Letters · 2022-08-31P03-18 Simultaneous detection and quantification of psilocybin and psilocin by gas chromatography coupled to mass spectrometry (GC-MS)Toxicology Letters · 2022-08-31To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.Experimental and Clinical Psychopharmacology · 2022-08-31Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response.Biomedicine & Pharmacotherapy · 2022-08-29Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.Expert Opinion on Drug Discovery · 2022-08-21The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world.Psychopharmacology · 2022-08-07Natural language signatures of psilocybin microdosing.Psychopharmacology · 2022-06-08Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.Substance Abuse Treatment Prevention and Policy · 2022-05-13Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.Unknown journal · 2022-05-12P388. Open Label Psilocybin Administration in Severely Treatment Resistant DepressionBiological Psychiatry · 2022-04-27Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.Journal of Psychopharmacology · 2022-04-06Production and extraction of psilocybin and psilocin from Psilocybe spp. mushroomsRevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia · 2022-04-05Evaluation of a quantitative analytical method for psilocin and psilocybin using HPLC-DADRevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia · 2022-04-05Psylocybin and Psilocin as new tools to fight depression: an overview of the Pharmacodynamic and pharmacokinetic mechanismsRevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia · 2022-04-05Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity.The International Journal of Neuropsychopharmacology · 2022-03-31Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.Frontiers in Pharmacology · 2022-03-30Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.Frontiers in Pharmacology · 2022-03-08Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats.Psychopharmacology · 2022-03-01The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.Journal of Psychopharmacology · 2022-02-28Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology · 2022-02-24Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.Journal of Psychopharmacology · 2022-01-31